Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Antitumor activity of colloidal silver on MCF-7 human breast cancer cells

Authors: Moisés A Franco-Molina, Edgar Mendoza-Gamboa, Crystel A Sierra-Rivera, Ricardo A Gómez-Flores, Pablo Zapata-Benavides, Paloma Castillo-Tello, Juan Manuel Alcocer-González, Diana F Miranda-Hernández, Reyes S Tamez-Guerra, Cristina Rodríguez-Padilla

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Colloidal silver has been used as an antimicrobial and disinfectant agent. However, there is scarce information on its antitumor potential. The aim of this study was to determine if colloidal silver had cytotoxic effects on MCF-7 breast cancer cells and its mechanism of cell death.

Methods

MCF-7 breast cancer cells were treated with colloidal silver (ranged from 1.75 to 17.5 ng/mL) for 5 h at 37°C and 5% CO2 atmosphere. Cell Viability was evaluated by trypan blue exclusion method and the mechanism of cell death through detection of mono-oligonucleosomes using an ELISA kit and TUNEL assay. The production of NO, LDH, and Gpx, SOD, CAT, and Total antioxidant activities were evaluated by colorimetric assays.

Results

Colloidal silver had dose-dependent cytotoxic effect in MCF-7 breast cancer cells through induction of apoptosis, shown an LD50 (3.5 ng/mL) and LD100 (14 ng/mL) (*P < 0.05), significantly decreased LDH (*P < 0.05) and significantly increased SOD (*P < 0.05) activities. However, the NO production, and Gpx, CAT, and Total antioxidant activities were not affected in MCF-7 breast cancer cells. PBMC were not altered by colloidal silver.

Conclusions

The present results showed that colloidal silver might be a potential alternative agent for human breast cancer therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wadhera Akhil MD, Fung Max: Systemic argyria associated with ingestion of coloidal silver. Dermatology. 2005, 11: 1 Wadhera Akhil MD, Fung Max: Systemic argyria associated with ingestion of coloidal silver. Dermatology. 2005, 11: 1
2.
go back to reference Kim JS, Kuk E: Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007, 3 (1): 95-101.CrossRef Kim JS, Kuk E: Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007, 3 (1): 95-101.CrossRef
3.
go back to reference Basu S, Jana S, Parde S, Pal T: Interaction of DNA bases with silver nanoparticles: assembly quantified throughout SPRS and SERS. Colloid Interface. 2008, 321 (2): 288-93.CrossRef Basu S, Jana S, Parde S, Pal T: Interaction of DNA bases with silver nanoparticles: assembly quantified throughout SPRS and SERS. Colloid Interface. 2008, 321 (2): 288-93.CrossRef
4.
go back to reference Lansdown AB: Silver in health care: antimicrobial effects and safety in use. Dermatology. 2006, 33: 17-34. Lansdown AB: Silver in health care: antimicrobial effects and safety in use. Dermatology. 2006, 33: 17-34.
5.
go back to reference Asha Rani PV, Prakash Hande M, Suresh Valiyaveettil: Anti-proliferative activity of silver nanoparticles. BMC Cell Biology. 2009, 10: 65CrossRef Asha Rani PV, Prakash Hande M, Suresh Valiyaveettil: Anti-proliferative activity of silver nanoparticles. BMC Cell Biology. 2009, 10: 65CrossRef
7.
go back to reference Gonzales Rengifo G, Gonzales Castañeda C, Rojas Tubeh: Overexpression of genes of glycolytic pathway enzymes in cancer cells. Acta Med. Peruana. 2007, 24 (3): 187-197. Gonzales Rengifo G, Gonzales Castañeda C, Rojas Tubeh: Overexpression of genes of glycolytic pathway enzymes in cancer cells. Acta Med. Peruana. 2007, 24 (3): 187-197.
8.
go back to reference Mazurek S, Zander U, Eigenbrodt E: In vitro effect of extracellular AMP on MCF-7 breast cancer cells: inhibition of glycolysis and cell proliferation. Cell Physiol. 1992, 153 (3): 539-49.CrossRef Mazurek S, Zander U, Eigenbrodt E: In vitro effect of extracellular AMP on MCF-7 breast cancer cells: inhibition of glycolysis and cell proliferation. Cell Physiol. 1992, 153 (3): 539-49.CrossRef
9.
go back to reference Narayanan Sriram: Enhancement of antioxidant defense system by Epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Bio Pharm. 2008, 31 (7): 1306-1311. Narayanan Sriram: Enhancement of antioxidant defense system by Epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Bio Pharm. 2008, 31 (7): 1306-1311.
10.
go back to reference Kim DW, Hong GH, Lee HH, Choi SH, Chun BG, Won CK, Hwang IK, Won MH: Effect of colloidal silver against the cytotoxicity of hydrogen peroxide and naphthazarin on primary cultured cortical astrocytes. Neuroscience. 2007, 117 (3): 387-400. Kim DW, Hong GH, Lee HH, Choi SH, Chun BG, Won CK, Hwang IK, Won MH: Effect of colloidal silver against the cytotoxicity of hydrogen peroxide and naphthazarin on primary cultured cortical astrocytes. Neuroscience. 2007, 117 (3): 387-400.
11.
go back to reference Balz Frei, Stephen Lawson: Vitamin C and cancer revisited. PNAS. 2008, 105 (32): 11037-11038.CrossRef Balz Frei, Stephen Lawson: Vitamin C and cancer revisited. PNAS. 2008, 105 (32): 11037-11038.CrossRef
Metadata
Title
Antitumor activity of colloidal silver on MCF-7 human breast cancer cells
Authors
Moisés A Franco-Molina
Edgar Mendoza-Gamboa
Crystel A Sierra-Rivera
Ricardo A Gómez-Flores
Pablo Zapata-Benavides
Paloma Castillo-Tello
Juan Manuel Alcocer-González
Diana F Miranda-Hernández
Reyes S Tamez-Guerra
Cristina Rodríguez-Padilla
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-148

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine